|
WO2004090537A2
|
|
Methods to individualize combination therapy
|
|
CA2527130A1
|
|
Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
|
|
WO2004087094A2
|
|
Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance
|
|
WO2004078677A2
|
|
Enhanced delivery of sphingolipids
|
|
CA2421316A1
|
|
Enhanced delivery of sphingolipids
|
|
TW200402312A
|
|
Improved polymer-lipid delivery vehicles
|
|
EP1458365A1
|
|
Improved polymer-lipid delivery vehicles
|
|
CA2469214A1
|
|
Improved polymer-lipid delivery vehicles
|
|
CA2467060A1
|
|
Lipid carrier compositions and methods for improved drug retention
|
|
AU2002340669A1
|
|
Lipid carrier compositions with enhanced blood stability
|
|
WO03022250A2
|
|
Unilamellar vesicles stabilized with short chain hydrophilic polymers
|
|
CA2449873A1
|
|
Cell penetrating therapeutic agents
|
|
CA2383259A1
|
|
Synergistic compositions
|
|
CA2365806A1
|
|
Improved polymer-lipid delivery vehicles
|
|
CA2361946A1
|
|
Delayed drug release using thermosensitive liposome
|
|
CA2361914A1
|
|
Improved cholesterol-free liposomes
|
|
AU5810601A
|
|
Lipid carrier compositions for improved drug retention
|
|
WO0141738A2
|
|
Lipid carrier compositions with protected surface reactive functions
|
